Analysts Offer Predictions for Cosmos Health FY2025 Earnings

Cosmos Health Inc. (NASDAQ:COSM) – Zacks Small Cap issued their FY2025 EPS estimates for Cosmos Health in a research report issued to clients and investors on Tuesday, January 13th. Zacks Small Cap analyst B. Sorensen anticipates that the company will earn ($0.25) per share for the year. The consensus estimate for Cosmos Health’s current full-year earnings is ($0.78) per share. Zacks Small Cap also issued estimates for Cosmos Health’s Q4 2025 earnings at ($0.04) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.11) EPS, Q1 2027 earnings at $0.00 EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at $0.03 EPS and FY2027 earnings at $0.07 EPS.

Other analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Cosmos Health to a “hold” rating in a research report on Saturday, September 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Cosmos Health Stock Performance

COSM opened at $0.45 on Thursday. Cosmos Health has a 1-year low of $0.28 and a 1-year high of $1.32. The stock has a market cap of $16.69 million, a P/E ratio of -0.59 and a beta of 5.37. The stock’s 50 day simple moving average is $0.56 and its 200 day simple moving average is $0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84.

Cosmos Health (NASDAQ:COSM) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The company had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%.

Insider Buying and Selling at Cosmos Health

In related news, CEO Grigorios Siokas acquired 168,472 shares of Cosmos Health stock in a transaction dated Monday, December 15th. The shares were acquired at an average cost of $0.42 per share, for a total transaction of $70,758.24. Following the completion of the transaction, the chief executive officer directly owned 6,628,457 shares of the company’s stock, valued at $2,783,951.94. The trade was a 2.61% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders acquired 1,086,095 shares of company stock valued at $583,096 over the last ninety days. Insiders own 25.10% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC grew its position in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 225,507 shares of the company’s stock after purchasing an additional 128,776 shares during the period. Citadel Advisors LLC owned 0.65% of Cosmos Health worth $250,000 at the end of the most recent quarter. 12.61% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Cosmos Health

Here are the key news stories impacting Cosmos Health this week:

• Positive Sentiment: Zacks Small‑Cap Research initiated coverage on Cosmos Health with a $4.50 per‑share valuation, highlighting projected revenue growth, margin expansion, U.S. expansion (ZipDoctor acquisition, Sky Premium Life launch), AI‑enabled R&D (Cloudscreen) and a path to improved free cash flow. This raises visibility and could attract buyer interest. GlobeNewswire: Zacks Initiates Coverage
• Positive Sentiment: CEO Grigorios Siokas purchased 113,185 shares (~$56.6k at $0.50) and has been an active buyer in recent weeks, increasing insider ownership — a strong insider signal that can support the share price over time. InsiderTrades: CEO Buys
• Neutral Sentiment: Zacks Small‑Cap also published forward EPS scenarios that show a path from negative 2025–2026 EPS to modest positive EPS by FY2027 (Zacks projects ~$0.07 FY2027), implying expectations of a turnaround but contingent on execution; these are model‑driven forecasts rather than confirmed outcomes.
• Negative Sentiment: Zacks’ report discloses Cosmos compensated the firm for the research — investors may discount the impartiality of the initiation and treat the $4.50 target as promotional rather than independent. GlobeNewswire: Disclosure
• Negative Sentiment: Recent fundamentals remain a concern: Cosmos missed on EPS in its last reported quarter (reported ($0.17) vs. consensus about ($0.01)), the consensus for the current year remains negative (~‑$0.78), and the stock has high volatility and low market cap—factors that can drive short‑term selling. MarketBeat: Financial Snapshot

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.